�鶹Ů��

The last time Ben Carson stepped onto a debate stage, he was asked about something he had never really questioned. Why had he endorsed the nutritional products of Mannatech, a Texas-based company that was forced to settle a 2009 wrongful marketing lawsuit? What did that endorsement say about his “judgment”? ... Yet, in defiance of the facts, Carson professed ignorance on the debate stage about any “relationship” with the company. He spent two days following the debate denouncing the questions about Mannatech as “propaganda.” And his most ardent supporters don’t care. (Weigel, 11/7)

Does Ben Carson have a “death panels” problem? Before he was a 2016 presidential candidate, Carson, a retired neurosurgeon, frequently raised questions about the high cost of end-of-life medical care — and asked whether patients should be able to pursue every available treatment. The statements touched on many of the most sensitive questions about care for the elderly. (Nather and Swetlitz, 11/8)

Hillary Rodham Clinton has long declined to endorse legalized medical or recreational marijuana at the federal level, but on Saturday, she added more specifics to her proposal to increase research into medical marijuana. Clinton said that she supports removing marijuana from a list of schedule 1 drugs, a classification that prevents federally-sponsored research into its effects. As a schedule 1 drug, marijuana is classified among the most dangerous drugs that the federal Drug Enforcement Agency regulates. (Phillip, 11/7)